Actively Recruiting
Phase I Study of CA-4948 Combined With FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer
Led by National Cancer Institute (NCI) · Updated on 2026-09-09
24
Participants Needed
13
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the side effects and best dose of CA-4948 emavusertib combined with chemotherapy drugs FOLFOX plus bevacizumab in treating patients with metastatic colorectal cancer, where the cancer has spread from the original site to other parts of the body. This phase I trial aims to assess the safety, tolerability, and anti-tumor activity of this combination, while also exploring effects on tumor biology and genetic markers. The study is sponsored by the National Cancer Institute NCI. Participants are assigned to one of two groups receiving CA-4948 orally twice daily on days 1 to 14 of each 14-day cycle. Both groups receive oxaliplatin, leucovorin, and fluorouracil intravenously on day 1 of each cycle. Bevacizumab is given intravenously on day 1 starting in cycle 1 for Group A and starting in cycle 2 for Group B. Treatment continues for up to 2 years unless the disease progresses or unacceptable side effects occur. After 2 years, patients may discuss continuing treatment with the study chair. Throughout the trial, patients may have blood samples taken, imaging scans such as CT, MRI, or PETCT, and tumor biopsies. Participants are monitored for dose-limiting toxicities and treatment-related side effects during the first two cycles, with ongoing safety assessments throughout treatment. Tumor response and survival outcomes are evaluated up to 12 months after treatment ends. Follow-up visits occur 30 days after treatment completion and then every 3 months for up to a year. The study also collects molecular profiling data to investigate biomarkers linked to treatment response and disease progression, helping researchers understand the therapys effects over time.
CONDITIONS
Brief Title
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here